Melanoma and other skin cancers:
Indications for LIBTAYO:
Treatment of metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC in patients who are not candidates for curative surgery or curative radiation.
Give by IV infusion over 30mins. 350mg every 3 weeks until disease progression or unacceptable toxicity. Dose modifications for adverse reactions: see full labeling.
Monitor for immune-related pneumonitis, colitis, hepatitis, endocrinopathies (adrenal insufficiency, hypophysitis, thyroid disorders, diabetes), nephritis, dermatologic, others; see full labeling. Evaluate clinical chemistries, including liver and thyroid function tests at baseline and periodically during treatment. Manage promptly as appropriate. Withhold for Grade 3 or 4 and certain Grade 2 immune-related adverse reactions. Permanently discontinue for Grade 4 or certain Grade 3 immune-related adverse reactions. Administer corticosteroids or consider other systemic immunosuppressants to control immune-related reactions until resolved. Institute hormone replacement therapy for endocrinopathies as needed. Monitor for infusion-related reactions; interrupt or slow infusion rate or permanently discontinue based on reaction severity. Embryo-fetal toxicity. Advise females of reproductive potential to use effective contraception during and for ≥4 months after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended (during and for ≥4 months after the last dose).
Human programmed death receptor-1 (PD-1)-blocking antibody.
Fatigue, rash, diarrhea, nausea, musculoskeletal pain, pruritus, constipation, decreased appetite; other immune-mediated adverse reactions (eg, neurological, cardiovascular, ocular, gastrointestinal, musculoskeletal and connective tissue, hematological, immunological).